Determinants of responses to oral vaccines in developing countries

Annales Nestle

Volumn 66, Issue 2, 2008, Pages 71-79

  Sack, David A ^a   Qadri, Firdausi ^b   Svennerholm, Ann Mari ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Breastfeeding; Cholera; Immune response; Malnutrition; Oral vaccines; Polio; Rotavirus; Shigellosis; Typhoid; Vitamin A; Zinc

Indexed keywords

ALBENDAZOLE; ANTIBODY; ASCORBIC ACID; BICARBONATE; BUFFER; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CHOLERAGARDE; CITRIC ACID; ESCHERICHIA COLI VACCINE; INACTIVATED VACCINE; LIVE VACCINE; MATERNAL ANTIBODY; ORAL POLIOMYELITIS VACCINE; PLACEBO; RETINOL; ROTAVIRUS VACCINE; SC 602; SECNIDAZOLE; SHIGELLA VACCINE; SIMIAN ROTAVIRUS VACCINE; TRACE ELEMENT; TRIPLE VACCINE; TYPHOID VACCINE; VACCINE; VITAMIN; ZINC;

ANTIBODY RESPONSE; ANTIBODY TITER; BREAST FEEDING; BREAST MILK; CALORIC INTAKE; CHILD HEALTH; CHOLERA; CLINICAL TRIAL; DEVELOPING COUNTRY; DIET SUPPLEMENTATION; DOSE RESPONSE; DYSENTERY; ENTEROBACTER INFECTION; GROUPS BY AGE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTIOUS DIARRHEA; INTESTINE INFECTION; INTESTINE MUCOSA; MALNUTRITION; MATERNAL NUTRITION; MUCOSAL DISEASE; NUTRITION; NUTRITIONAL STATUS; PARASITOSIS; PLACENTA; POLIOMYELITIS; PREGNANCY; PROTEIN MALNUTRITION; REVIEW; ROTAVIRUS; SOCIAL STATUS; TRAVELLER DIARRHEA; TREATMENT RESPONSE; TYPHOID FEVER; VIRUS INFECTION; VITAMIN SUPPLEMENTATION;

EID: 47549117914     PISSN: 05178606     EISSN: 16614011     Source Type: Journal    
DOI: 10.1159/000129624     Document Type: Review

References (74)

1. Moore SE, Goldblatt D, Bates CJ, Prentice AM: Impact of nutritional status on antibody responses to different vaccines in undernourished Gambian children. Acta Paediatr 2003;92:170-176.
2. Faden H: Results of a clinical study of polio vaccine: the Buffalo experience. Pediatr Infect Dis J 1991;10:973-975.
3. Agarwal A, Sharma D, Kumari S, Khare S: Antibody response to three doses of standard and double dose of trivalent oral polio vaccine. Indian Pediatr 1991;28:1141-1145.
4. Sabin AB: Vaccination against poliomyelitis in economically underdeveloped countries. Bull World Health Organ 1980;58:141-157.
5. John TJ, Jayabal P: Oral polio vaccination of children in the tropics. 1. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972;96:263-269.
6. Sutter RW, Suleiman AJ, Malankar P, et al: Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000;343:767-773.
7. Triki H, Abdallah MV, Ben AR, et al: Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine 1997;15:1123-1129.
8. Swartz TA, Skalska P, Gerichter CG, Cockburn WC: Routine administration of oral polio vaccine in a subtropical area. Factors possibly influencing seroconversion rates. J Hyg (Lond) 1972;70:719-726.
9. Lepow ML, Warren RJ, Gray N, et al: Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 1961;264:1071-1078.
10. Plotkin SA, Katz M, Brown RE, Pagano JS: Oral poliovirus vaccination in newborn African infants. The inhibitory effect of breast feeding. Am J Dis Child 1966;111:27-30.
11. Katz M, Plotkin SA: Oral polio immunization of the newborn infant;a possible method for overcoming interference by ingested antibodies. J Pediatr 1968;73:267-270.
12. John TJ, Devarajan LV, Luther L, Vijayarathnam P: Effect of breast-feeding on seroresponse of infants to oral poliovirus vaccination. Pediatrics 1976;57:47-53.
13. Myaux JA, Unicomb L, Besser RE, et al: Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996;15:204-209.
14. Bhaskaram P, Nair KM, Hemalatha P, et al: Systemic and mucosal immune response to polio vaccination with additional dose in newborn period. J Trop Pediatr 1997;43:232-234.
15. Chopra K, Kundu S, Chowdhury DS: Antibody response of infants in tropics to five doses of oral polio vaccine. J Trop Pediatr 1989;35:19-23.
16. Bahl R, Bhandari N, Wahed MA, et al: Vitamin A supplementation of women postpartum and of their infants at immunization alters breast milk retinol and infant vitamin A status. J Nutr 2002;132:3243-3248.
17. Vesikari T, Isolauri E, d'Hondt E, et al: Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;i:977-981.
18. Hanlon P, Hanlon L, Marsh V, et al: Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;i:1342-1345.
19. Georges-Courbot MC, Monges J, Siopathis MR, et al: Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991;142:405-411.
20. De Mol P, Zissis G, Butzler JP, et al: Failure of live, attenuated oral rotavirus vaccine. Lancet 1986;ii:108.
21. Joensuu J, Koskenniemi E, Pang XL, Vesikari T: Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-1209.
22. Rennels MB, Glass RI, Dennehy PH, et al: Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996;97:7-13.
23. Lanata CF, Midthun K, Black RE, et al: Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996;174:268-275.
24. Linhares AC, Gabbay YB, Mascarenhas JD, et al: Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996;74:491-500.
25. Perez-Schael I, Guntinas MJ, Perez M, et al: Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-1187.
26. Linhares AC, Lanata CF, Hausdorff WP, et al: Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. Pediatr Infect Dis J 1999;18:1001-1006.
27. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
28. Vesikari T, Matson DO, Dennehy P, et al: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
29. Pichichero ME: Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. J Infect Dis 1990;162:753-755.
30. Rennels MB, Wasserman SS, Glass RI, Keane VA: Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group. Pediatrics 1995;96:1132-1136.
31. Linhares AC, Carmo KB, Oliveira KK, et al: Nutritional status in relation to the efficacy of the rhesus-human reassortant, tetravalent rotavirus vaccine (RRV-TV) in infants from Belem, Para state, Brazil. Rev Inst Med Trop Sao Paulo 2002;44:13-16.
32. Perez-Schael I, Salinas B, Tomat M, et al: Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis 2007;196:537-540.
33. Lin FY, Ho VA, Khiem HB, et al: The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001;344:1263-1269.
34. Murphy JR, Grez L, Schlesinger L, et al: Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect Immun 1991;59:4291-4293.
35. Cryz SJ Jr, Vanprapar N, Thisyakorn U, et al: Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993;61:1149-1151.
36. Cooper PJ, Chico M, Sandoval C, et al: Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun 2001;69:1574-1580.
37. Lagos R, Avendano A, Horwitz I, et al: Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults. Rev Med Chil 1993;121:857-863.
38. Simanjuntak CH, O'Hanley P, Punjabi NH, et al: Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993;168:1169-1176.
39. Suharyono, Simanjuntak C, Witham N, et al: Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992;340:689-694.
40. Richie EE, Punjabi NH, Sidharta YY, et al: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000;18:2399-2410.
41. Lagos R, Fasano A, Wasserman SS, et al: Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999;180:1709-1712.
42. Sack DA, Sack RB, Shimko J, et al: Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis 1997;176:201-205.
43. Cohen MB, Giannella RA, Bean J, et al: Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002;70:1965-1970.
44. Kenner JR, Coster TS, Taylor DN, et al: Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 1995;172:1126-1129.
45. Qadri F, Chowdhury MI, Faruque SM, et al: Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007;25:231-238.
46. Sack DA, Shimko J, Sack RB, et al: Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect Immun 1997;65:2107-2111.
47. Clemens JD, Sack DA, Harris JR, et al: Field trial of oral cholera vaccines in Bangladesh. Lancet 1986;ii:124-127.
48. Holmgren J, Clemens J, Sack DA, Svennerholm AM: New cholera vaccines. Vaccine 1989;7:94-96.
49. Trach DD, Clemens JD, Ke NT, et al: Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997;349:231-235.
50. Clemens JD, Sack DA, Harris JR, et al: Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990;335:270-273.
51. Concha A, Giraldo A, Castaneda E, et al: Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Bull Pan Am Health Organ 1995;29:312-321.
52. Sanchez JL, Vasquez B, Begue RE, et al: Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994;344:1273-1276.
53. Taylor DN, Cardenas V, Sanchez JL, et al: Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 2000;181:1667-1673.
54. Lucas ME, Deen JL, von Seidlein L, et al: Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005;352:757-767.
55. Taylor DN, Cardenas V, Perez J, et al: Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Am J Trop Med Hyg 1999;61:869-873.
56. Clemens JD, Stanton BF, Chakraborty J, et al: B subunit whole-cell and whole-cell only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 1987;155:79-85.
57. Sack DA, Clemens JD, Huda S, et al: Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 1991;164:407-411.
58. Hallander HO, Paniagua M, Espinoza F, et al: Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002;21:138-145.
59. Glass RI, Svennerholm AM, Stoll BJ, et al: Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine. Pediatr Infect Dis J 1989;8:105-109.
60. Albert MJ, Qadri F, Wahed MA, et al: Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis 2003;187:909-913.
61. Qadri F, Ahmed T, Wahed MA, et al: Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine. Vaccine 2004;22:416-421.
62. Glass RI, Stoll BJ: The protective effect of human milk against diarrhea. A review of studies from Bangladesh. Acta Paediatr Scand Suppl 1989;351:131-136.
63. Trach DD, Cam PD, Ke NT, et al: Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull World Health Organ 2002;80:2-8.
64. Svennerholm AM, Steele D: Microbial-gut interactions in health and disease. Progress in enteric vaccine development. Best Pract Res Clin Gastroenterol 2004;18:421-445.
65. Savarino SJ, Hall ER, Bassily S, et al: Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 2002;21:322-330.
66. Qadri F, Ahmed T, Ahmed F, et al: Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine 2006;24:1726-1733.
67. Walker RI, Steele D, Aguado T: Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 2007;25:2545-2566.
68. Sack DA, Shimko J, Torres O, et al: Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 2007;25:4392-4400.
69. Coster TS, Hoge CW, VanDeVerg LL, et al: Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999;67:3437-3443.
70. Anonymous: Future needs and directions for Shigella vaccines. Wkly Epidemiol Rec 2006;81:51-58.
71. Cohen D, Ashkenazi S, Green MS, et al: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997;349:155-159.
72. Wellinghausen N: Immunobiology of gestational zinc deficiency. Br J Nutr 2001;85(suppl 2):S81-S86.
73. Golden MH, Jackson AA, Golden BE: Effect of zinc on thymus of recently malnourished children. Lancet 1977;ii:1057-1059.
74. Walker CF, Black RE: Zinc and the risk for infectious disease. Annu Rev Nutr 2004;24:255-275.